OCULAR

EXPERT VIEW

Michael O'Rourke

SUSTAINED-RELEASE OCULAR DELIVERY TECHNOLOGIES

Michael O'Rourke discusses the advances in the development and launching of sustained-release ocular drug delivery systems seen in recent years.

OCULAR

Donna Bibber

Micro Engineering Solutions

SCALEABILITY OF MICRO INTRAOCULAR IMPLANTS AND DEVICES

Donna Bibber discusses some of these micro-intraocular implants and devices and the scalability challenges associated with each, from the perspective of a plastics engineer.

OCULAR

Chris Muller

Mati Therapeutics

THERAPY WITHOUT DROPS: A REALITY

Chris Muller and Deepank Utkhede introduce Mati Therapeutics' Evolute^® ocular delivery system, a non-invasive, sustained-release platform that combines a novel punctal plug with a sustained release drug eluting core.

OCULAR

Dr Shikha P Barman

Integral BioSystems

INTRODUCING OCUSURF™ NANOSTRUCTURED EMULSION AS A 505(B)(2) STRATEGY

Shikha P Barman describes how Integral Biosystems is developing a series of ophthalmic products with its OcuSurf platform.

OCULAR

Dr Paul Ashton

EyePoint Pharmaceuticals

PSIVIDA AND OPHTHALMIC DRUG DELIVERY

Paul Ashton describes how much of the progress that has been made recently in the treatment of ophthalmic diseases can be ascribed to effective drug delivery systems, and outlines some of the delivery technologies and resulting products for which pSivida has been responsible.

OCULAR

Dr Marc Horner

ANSYS, Inc

MODELLING OCULAR DELIVERY USING COMPUTATIONAL FLUID DYNAMICS

Paul Missel and Marc Horner describe the use of computational fluid dynamics simulations to predict drug flow and temperature inside the eye, and provide examples of applications modelling.

EXPERT VIEW

Dr Paul Ashton

HUGE THERAPEUTIC ADVANCES: BIGGER DRUG DELIVERY OPPORTUNITIES

Paul Ashton gives an introduction into the current state of the ophthalmics market.

OCULAR

Dr Dieter Scherer

Novaliq

AN INTEGRATED PIPELINE OF OPHTHALMIC PRODUCTS BASED ON EYESOL™ DELIVERY TECHNOLOGY

Dieter Scherer describes two of Novaliq’s most advanced products: NovaTears^®, a wetting agent for the ocular surface, and CyclASol^®, a clear formulation of Cyclosporin A. Both products use Novaliq’s semifluorinated alkane technology, EyeSol^®.

EXPERT VIEW

Dr Ilva D Rupenthal

OCULAR DRUG DELIVERY TECHNOLOGIES: EXCITING TIMES AHEAD

Ilva Rupenthal gives a sector overview of the occular drug delivery space.

OCULAR

Dr Janice Cacace

CoreRx

EXCIPIENT SELECTION FOR OPHTHALMIC OINTMENTS

Janice Cacace and Travis Webb describe the physical properties of petrolatums as they relate to the comfort and efficacy of formulations of ophthalmic ointments.

Michael O'Rourke

COMPANY SHOWCASE: GRAYBUG

GrayBug is advancing ophthalmic therapeutics through a continuum of polymerbased drug delivery platforms and innovative products offering sustained competitive advantage.

OCULAR

Brian McMillan

CoreRx

CURRENT AND FUTURE OPHTHALMIC FORMULATION AND PROCESS DEVELOPMENT TRENDS

Brian McMillan provides some insights into his personal experiences in the development of ophthalmic products and the significant role of innovative delivery systems in improving efficacy and reducing side-effects.

OCULAR

Dr Daniel A Bernards

Oculinea

ZERO-ORDER SUSTAINED DRUG DELIVERY TO THE RETINA FROM A NANOPOROUS FILM DEVICE

Daniel Bernards, Robert Bhisitkul and Tejal Desai discuss the development of a nanoporous membrane-based implant which can significantly improve drug delivery to the back of the eye.

OCULAR

Dr Shikha P Barman

Integral BioSystems

REVIEW OF PRESENT TECHNOLOGIES & STEPS FORWARD

Shikha Barman provides an overview of the current state of play in the ocular drug delivery market.

OCULAR

Dr Tomas Navratil

IMPROVING OUTCOMES IN OPHTHALMOLOGY VIA SUSTAINED DRUG DELIVERY

Tomas Navratil, Benjamin Maynor and Benjamin Yerxa describe the company’s particle engineering technology and its application in improving the delivery of prostaglandin analogues and anti-VEGF therapy.

OCULAR

Badre Hammond

Next Breath

REDUCE RISKS, MITIGATE FAILURE & DRIVE TIMELINES IN A COMPETITIVE MARKET

Badre Hammond, Shailuja Somaraju and Julie Suman highlight key considerations and present strategies to reduce risk and ultimately accelerate the process for gaining approval of an ophthalmic product, with a focus on the US.

OCULAR

Rick Coulon

Encompass Pharmaceutical Services

COMPANY PROFILE: ENCOMPASS

Encompass Pharma, based in Norcross, GA, US, was formed in 2004 by a highly experienced team of ophthalmic development and analytical scientists.

OCULAR

Donna Bibber

Micro Engineering Solutions

MICRO OPHTHALMIC OCULAR IMPLANTS

Donna Bibber explores one market segment in which micro manufacturing has played and will continue to play a significant role in worldwide growth in the next five years … ophthalmic devices.

OCULAR

Dr Robert Langer

Kala Bio

BREAKTHROUGH NANOTECHNOLOGY ENHANCES DELIVERY TO THE FRONT AND BACK OF THE EYE

Hongming Chen and Robert Langer discuss applications of the company’s Mucus Penetrating Particle nanotechnology in ophthalmic drug delivery.